83 FR 15391 - National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 69 (April 10, 2018)

Page Range		15391-15391
FR Document		2018-07268

Federal Register, Volume 83 Issue 69 (Tuesday, April 10, 2018)

[Federal Register Volume 83, Number 69 (Tuesday, April 10, 2018)]
[Notices]
[Page 15391]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-07268]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney Diseases; 
Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel; CRIC Ancillary Study 
(R01)
    Date: May 17, 2018.
    Time: 3:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Two Democracy Plaza, 6707 
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Jason D. Hoffert, Ph.D., Scientific Review 
Officer, Review Branch, DEA, NIDDK, National Institutes of Health, 
Room 7343, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, (301) 
496-9010, hoffertj@niddk.nih.gov.

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel; Pragmatic Research and 
Natural Experiments.
    Date: May 18, 2018.
    Time: 10:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Two Democracy Plaza, 6707 
Democracy Boulevard, Bethesda, MD 20892 Telephone Conference Call).
    Contact Person: Michele L. Barnard, Ph.D., Scientific Review 
Officer, Review Branch, DEA, NIDDK, National Institutes of Health, 
Room 7353, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, (301) 
594-8898, barnardm@extra.niddk.nih.gov.

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel; PAR-18-012: NIDDK 
Program Projects (P01).
    Date: May 24, 2018.
    Time: 12:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Two Democracy Plaza, 6707 
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Dianne Camp, Ph.D., Scientific Review Officer, 
Review branch, DEA, NIDDK, National Institutes of Health, Room 7013, 
6707 Democracy Boulevard, Bethesda, MD 20892-2542, (301) 594-7682, 
campd@extra.niddk.nih.gov.

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel; P01 Application Bladder 
Physiology.
    Date: May 31, 2018.
    Time: 2:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Two Democracy Plaza, 6707 
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Ryan G. Morris, Ph.D., Scientific Review 
Officer, review branch, DEA, NIDDK, National Institutes of Health, 
Room 7015, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, (301) 
594-4721, ryan.morris@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology 
and Hematology Research, National Institutes of Health, HHS)

    Dated: April 4, 2018.
David D. Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-07268 Filed 4-9-18; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 83, No. 69 / Tuesday, April 10, 2018 / Notices 15391

FOR FURTHER INFORMATION CONTACT: individuals associated with the grant Bethesda, MD 20892–2542, (301) 594–4721,
Althea Cuff, Center for Drug Evaluation applications, the disclosure of which ryan.morris@nih.gov.
and Research, Food and Drug would constitute a clearly unwarranted (Catalogue of Federal Domestic Assistance
Administration, 10903 New Hampshire invasion of personal privacy. Program Nos. 93.847, Diabetes,
Ave., Silver Spring, MD 20993–0002, Endocrinology and Metabolic Research;
Name of Committee: National Institute of 93.848, Digestive Diseases and Nutrition
301–796–4061, Fax: 301–796–9856, Diabetes and Digestive and Kidney Diseases Research; 93.849, Kidney Diseases, Urology
email: althea.cuff@fda.hhs.gov. Special Emphasis Panel; CRIC Ancillary and Hematology Research, National Institutes
SUPPLEMENTARY INFORMATION: Under Study (R01) of Health, HHS)
section 529 of the FD&C Act (21 U.S.C. Date: May 17, 2018.
Time: 3:00 p.m. to 4:00 p.m. Dated: April 4, 2018.
360ff), which was added by FDASIA,
Agenda: To review and evaluate grant David D. Clary,
FDA will report the issuance of rare
applications. Program Analyst, Office of Federal Advisory
pediatric disease priority review
Place: National Institutes of Health, Two Committee Policy.
vouchers and the approval of products Democracy Plaza, 6707 Democracy [FR Doc. 2018–07268 Filed 4–9–18; 8:45 am]
for which a voucher was redeemed. Boulevard, Bethesda, MD 20892 (Telephone
FDA has determined that the Conference Call).
BILLING CODE 4140–01–P

following approved drugs meet the Contact Person: Jason D. Hoffert, Ph.D.,
redemption criteria: Scientific Review Officer, Review Branch,
• PRALUENT (alirocumab) approved DEA, NIDDK, National Institutes of Health, DEPARTMENT OF HEALTH AND
July 24, 2015, Room 7343, 6707 Democracy Boulevard, HUMAN SERVICES
• SOLIQUA (insulin glargine and Bethesda, MD 20892–2542, (301) 496–9010,
lixisenatide) approved November 21, hoffertj@niddk.nih.gov. National Institutes of Health
2016, and Name of Committee: National Institute of National Institute of Diabetes and
• JULUCA (dolutegravir and Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Pragmatic Research
Digestive and Kidney Diseases; Notice
rilpivirine) approved November 21,
and Natural Experiments. of Closed Meetings
2017.
For further information about the Rare Date: May 18, 2018. Pursuant to section 10(d) of the
Pediatric Disease Priority Review Time: 10:00 a.m. to 4:00 p.m. Federal Advisory Committee Act, as
Agenda: To review and evaluate grant
Voucher Program and for a link to the amended, notice is hereby given of the
applications.
full text of section 529 of the FD&C Act, Place: National Institutes of Health, Two following meetings.
go to https://www.fda.gov/ForIndustry/ Democracy Plaza, 6707 Democracy The meetings will be closed to the
DevelopingProductsforRareDiseases Boulevard, Bethesda, MD 20892 Telephone public in accordance with the
Conditions/RarePediatricDiseasePriority Conference Call). provisions set forth in sections
VoucherProgram/default.htm. For Contact Person: Michele L. Barnard, Ph.D., 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
further information about PRALUENT Scientific Review Officer, Review Branch, as amended. The grant applications and
(alirocumab), SOLIQUA (insulin DEA, NIDDK, National Institutes of Health, the discussions could disclose
glargine and lixisenatide), and JULUCA Room 7353, 6707 Democracy Boulevard, confidential trade secrets or commercial
Bethesda, MD 20892–2542, (301) 594–8898,
(dolutegravir and rilpivirine), go to the property such as patentable material,
barnardm@extra.niddk.nih.gov.
‘‘Drugs@FDA’’ website at https:// and personal information concerning
Name of Committee: National Institute of
www.accessdata.fda.gov/scripts/cder/ individuals associated with the grant
Diabetes and Digestive and Kidney Diseases
daf/. Special Emphasis Panel; PAR–18–012: applications, the disclosure of which
Dated: April 4, 2018. NIDDK Program Projects (P01). would constitute a clearly unwarranted
Leslie Kux, Date: May 24, 2018. invasion of personal privacy.
Associate Commissioner for Policy. Time: 12:00 p.m. to 3:00 p.m. Name of Committee:
Agenda: To review and evaluate grant National Institute of Diabetes and Digestive
[FR Doc. 2018–07256 Filed 4–9–18; 8:45 am] applications. and Kidney Diseases Special Emphasis Panel;
BILLING CODE 4164–01–P Place: National Institutes of Health, Two Time-Sensitive Obesity Research.
Democracy Plaza, 6707 Democracy Date: May 1, 2018.
Boulevard, Bethesda, MD 20892 (Telephone Time: 1:00 p.m. to 2:30 p.m.
DEPARTMENT OF HEALTH AND Conference Call). Agenda: To review and evaluate grant
HUMAN SERVICES Contact Person: Dianne Camp, Ph.D., applications.
Scientific Review Officer, Review branch, Place: National Institutes of Health, Two
National Institutes of Health DEA, NIDDK, National Institutes of Health, Democracy Plaza, 6707 Democracy
Room 7013, 6707 Democracy Boulevard, Boulevard, Bethesda, MD 20892 (Telephone
National Institute of Diabetes and Bethesda, MD 20892–2542, (301) 594–7682, Conference Call).
Digestive and Kidney Diseases; Notice campd@extra.niddk.nih.gov. Contact Person: Michele L. Barnard, Ph.D.,
of Closed Meetings Name of Committee: National Institute of Scientific Review Officer, Review Branch,
Diabetes and Digestive and Kidney Diseases DEA, NIDDK, National Institutes of Health
Pursuant to section 10(d) of the Special Emphasis Panel; P01 Application Room 7353, 6707 Democracy Boulevard,
Federal Advisory Committee Act, as Bladder Physiology. Bethesda, MD 20892–2542, (301) 594–8898
amended, notice is hereby given of the Date: May 31, 2018. barnardm@extra.niddk.nih.gov.
following meetings. Time: 2:00 p.m. to 5:00 p.m. Name of Committee: National Institute of
The meetings will be closed to the Agenda: To review and evaluate grant Diabetes and Digestive and Kidney Diseases
public in accordance with the applications. Special Emphasis Panel; PAR–17–270:
daltland on DSKBBV9HB2PROD with NOTICES

provisions set forth in sections Place: National Institutes of Health, Two NIDDK Central Repositories Non-renewable
Democracy Plaza, 6707 Democracy Samples Access (X01).
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Boulevard, Bethesda, MD 20892 (Telephone Date: May 2, 2018.
as amended. The grant applications and Conference Call). Time: 12:00 p.m. to 2:00 p.m.
the discussions could disclose Contact Person: Ryan G. Morris, Ph.D., Agenda: To review and evaluate grant
confidential trade secrets or commercial Scientific Review Officer, review branch, applications.
property such as patentable material, DEA, NIDDK, National Institutes of Health, Place: National Institutes of Health, Two
and personal information concerning Room 7015, 6707 Democracy Boulevard, Democracy Plaza, 6707 Democracy

VerDate Sep<11>2014 16:56 Apr 09, 2018 Jkt 244001 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 E:\FR\FM\10APN1.SGM 10APN1

Document Created: 2018-04-09 23:51:52
Document Modified: 2018-04-09 23:51:52

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		May 17, 2018.
FR Citation		83 FR 15391

83 FR 15391 - National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 83, Issue 69 (April 10, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health